This study is looking at a new medicine called CVN424 for people with early Parkinson's Disease (PD). PD is a condition that affects movement, causing symptoms like shaking and stiffness. The study will last for 12 weeks and will compare CVN424 to a placebo, which is a pill with no medicine in it. A placebo helps researchers see how well the real medicine works. Participants will take either CVN424 or the placebo and will have their motor (movement) skills checked. The study wants to see if CVN424 helps improve movement and other functions in people with early PD who haven’t started other PD treatments.

• The study lasts 12 weeks and involves taking tablets and attending scheduled visits.
• Participants must not have taken PD treatments like dopamine agonists for more than 28 days before starting.
• Participants must be at least 30 years old and meet certain health criteria to join.